EMA recommends marketing authorization for donanemab (Kisunla)
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
The 78th World Health Assembly agrees to extend the Global Action Plan on the Public Health Response to Dementia
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Older persons and dementia organisations raise concerns relating to the new pandemic treaty
A joint letter was submitted in anticipation of the 3rd session of the World Health Organization's Intergovernmental Negotiating Body on 5-7 December.
Lecanemab results attract widespread international attention at CTAD
Eisai presented the results of their confirmatory Phase 3 clinical trial (CLARITY AD) at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, which many are hailing as positive news for the field.
Gantenerumab fails to meet primary goal
In a press release, Roche confirmed that the Phase 3 GRADUATE studies for gantenerumab did not meet their primary goal of slowing clinical decline in people with early Alzheimer’s disease.
Bringing the best to life at Summerset
In this blog from Orquidea Tamayo Mortera of Summerset, one of New Zealand’s leading independent retirement village operators, Orquidea writes about how Summerset is responding and rising to the evolving challenges of care for people living with dementia through innovative ways.
Values20 launches communiqué in preparation for G20
The communiqué calls on the G20 to lead the way in being truly values-driven for global impact and to operate in an environment where there is an agreement on shared values, clarity on unique values across nations, understanding of the values of difference and more.
Young onset dementia and post-diagnostic support
In this blog from Samantha Loi of the Australian Young Onset Dementia Special Interest Group (YOD-SIG), Samantha examines the complexities experienced by people living with young onset dementia when accessing post-diagnostic care, support and treatment.
TauRx reports top line results of their Phase 3 study LUCIDITY
Results from the LUCIDTY Phase 3 study suggests initial positive results for early and mild to moderate Alzheimer’s Disease
WISH launches new palliative care report with ADI
‘Integrating palliative care for older adults’ was written with ADI, The Worldwide Hospice Palliative Care Alliance (WHPCA), SANAD Hospice Lebanon and Hamad Medical Corporation (HMC).